


| Key | % Net Assets |
|---|---|
| 5.0% | |
| 4.0% | |
| 3.7% | |
| 3.5% | |
| 83.8% |
| Name | % Net Assets |
|---|---|
| GlaxoSmithKline | 5.0% |
| BP | 4.0% |
| Vodafone Group | 3.7% |
| HSBC Holdings | 3.5% |
| Lloyds Banking Group | 3.2% |
| AstraZeneca | 3.2% |
| Legal & General Group | 3.1% |
| Reed Elsevier | 3.1% |
| Unilever | 2.7% |
| Schroder Recovery Fund | 2.5% |
| Key | % Net Assets |
|---|---|
| 26.40% | |
| 15.40% | |
| 13.20% | |
| 11.50% | |
| 8.90% |
| Date | 02-Mar-2022 |
|---|---|
| NAV | 2,294.00p |
| Currency | GBP |
| Change | -43.00p |
| % | -1.84% |
| YTD change | 2,294.00p |
| YTD % | n/a |
| Fund Inception | 30/04/1987 |
|---|---|
| Fund Manager | Alex Breese |
| TER | 1.67 (20-Jun-2012) |
| Minimum Investment | |
|---|---|
| Initial | £1000 |
| Additional | n/a |
| Savings | £50 |
| Charges | |
|---|---|
| Initial | n/a |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.02 |
| Sharpe ratio | 0.09 |
You are here: research